TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2539346
Drug: Ro 03-8799
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 03-8799 (0.75 g/m2) and SR 2508 (2 g/m2) administered three times per week for 15 doses
Study: 2539346
Drug: Ro 03-8799
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 03-8799 (0.75 g/m2) and SR 2508 (2 g/m2) administered three times per week for 12 doses
Study: 2539346
Drug: Ro 03-8799
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 03-8799 and SR 2508 combination
Study: 31223399
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of ketoprofen 100mg
Study: 31223399
Drug: Lidocaine and
Normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and prilocaine topical cream
Study: 27558280
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil (AZL-M) (all doses)
Study: 27558280
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OLM) 20 mg
Study: 23250194
Drug: Concurrent physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent physical activity (PA)
Study: 19293130
Drug: Immediate switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate switch to 4.6 mg/24 h rivastigmine transdermal patch
Study: 19293130
Drug: Delayed switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed switch to 4.6 mg/24 h rivastigmine transdermal patch
Study: 20395684
Drug: Donepezil 5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5-10 mg/day
Study: 17501956
Drug: TCHM (Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCHM (Chinese herbal medicine concoction), 3 capsules twice daily for 12 weeks
Study: 17501956
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 capsules twice daily for 12 weeks
Study: 17501956
Drug: TCHM (Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCHM (Chinese herbal medicine concoction)
Study: 15494274
Drug: Early hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Early hydrocortisone treatment (n = 9)
Study: 15494274
Drug: Early hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Early hydrocortisone treatment
Study: 11847472
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (0.15 IU/kg/day)
Study: 2889554
Drug: Bopindolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol (2 mg, administered orally)
Study: 2889554
Drug: Bopindolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol (2 to 4 mg, administered orally)
Study: 28857785
Drug: i‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: i‐gel
Study: 27160490
Drug: Intrathecal magnesium
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal magnesium sulphate (375 μg/rat) prior to intrathecal morphine (10 μg/rat)
Study: 27160490
Drug: Intrathecal mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal mixture of 1 mg of morphine with 3 mL hyperbaric 0.5% bupivacaine
Study: 27160490
Drug: Intrathecal mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal mixture of morphine with bupivacaine and 50 mg of magnesium sulphate
Study: 27160490
Drug: Intrathecal mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal mixture of morphine bupivacaine plus IV 20 mg/kg of magnesium sulphate as a loading dose over 15 min, followed by infusion at a rate of 10 mg/kg/h
Study: 24895810
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (PE) plus standard medical treatment
Study: 22266041
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (E1594 and E4599)
Study: 22266041
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment (E4599)
Study: 18408919
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tandospirone
Study: 15900355
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (non-chewing controls)
Study: 10875051
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (mainly antidepressants)
Study: 10875051
Drug: Cognitive‐behaviour therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behaviour therapy
Study: 10875051
Drug: Self‐help therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐help therapy
Study: 26869460
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily physical exercise unit at school for 4 years
Study: 26869460
Drug: Conventional school
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional school sports twice a week
Study: 26869460
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily physical exercise unit at school
Study: 21851602
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract containing 150 mg EGCG two times daily
Study: 16367882
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 mg once daily plus glipizide 10 mg twice daily
Study: 16367882
Drug: Sulphonylurea (SU)
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea (SU) dose escalation plus placebo
Study: 16367882
Drug: Sulphonylurea (SU)
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea (SU) dose escalation
Study: 12635001
Drug: Concentrated ambient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated ambient particulates (CAP) at an average concentration of 174 micro g/m(3) for 2 hours with alternating rest-exercise periods.
Study: 1360991
Drug: Phenindamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenindamine (25 mg)
Study: 6581756
Drug: Bright artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright artificial light therapy
Study: 23178916
Drug: Adalimumab plus
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab plus adjunctive topical therapy (calcipotriol/betamethasone dipropionate)
Study: 23178916
Drug: Adalimumab plus
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab plus matching topical vehicle (monotherapy)
Study: 15578006
Drug: olanzapine (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine (10‐20 mg/day)
Study: 15578006
Drug: amisulpride (400‐800
Approvals — FDA: no, EMA: no, PMDA: no
Description: amisulpride (400‐800 mg/day)
Study: 6340453
Drug: Verapamil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.2 mg/kg over 10 minutes)
Study: 27548249
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy (6 mg·kg·day) plus placebo
Study: 27548249
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy (6 mg·kg·day) plus vitamin E (18 mg/day)
Study: 27548249
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy (6 mg·kg·day) plus placebo and vitamin E
Study: 15876664
Drug: Compound probability
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound probability density function parameters including the speckle factor and K distribution parameter
Study: 7828131
Drug: VAD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAD plus oral verapamil (VAD/v)
Study: 1964218
Drug: Local step-by-step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local step-by-step intrapulmonary administration of glucocorticosteroids (GCS)
Study: 24411286
Drug: Ultrasound-guided para-aneurysmal
Normalized name: para-cresol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided para-aneurysmal saline injection (PASI)
Study: 15220031
Drug: donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil (5 mg/day)
Study: 15220031
Drug: donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil (5 or 10 mg/day)
Study: 9683718
Drug: iodixanol (Visipaque;
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol (Visipaque; 320 mg I/ml)
Study: 9683718
Drug: iohexol (Omnipaque;
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol (Omnipaque; 300 mg I/ml)
Study: 8023589
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drugs (NSAID)
Study: 3072358
Drug: Ketoprofen 225
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 225 mg
Study: 26400874
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of antihypertensive medications
Study: 29211509
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of antihypertensive medications
Study: 23422867
Drug: Isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone soy protein (ISP) supplementation, 154 mg daily for 3 years
Study: 19371188
Drug: Conventional-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose statin therapy
Study: 14503436
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy program for mobility
Study: 10797496
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment for localized prostate cancer
Study: 10797496
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of localized disease
Study: 10797496
Drug: Screening procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Screening procedures and treatments for localized prostate cancer
Study: 1443705
Drug: M-K-A (midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-K-A (midazolam 0.5 mg/kg, ketamine 3 mg/kg, atropine 0.02 mg/kg)
Study: 1443705
Drug: M-A (midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-A (midazolam 0.5 mg/kg, atropine 0.02 mg/kg)
Study: 1443705
Drug: K-A (ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-A (ketamine 3 mg/kg, atropine 0.02 mg/kg)
Study: 1443705
Drug: A (atropine
Normalized name: B-Donna (atropine sulfate 0.0194 MG / hyoscyamine sulfate 0.1037 MG / phenobarbital 16.2 MG / scopolamine hydrobromide 0.0065 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A (atropine 0.02 mg/kg)
Study: 29949323
Drug: Mild hormonally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hormonally stimulated cycle by low dose Clomiphene Citrate (n=30)
Study: 12435668
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) infusion of 400 mg ciprofloxacin over 60 min
Study: 12435668
Drug: Oral (p.o.)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (p.o.) dose of 500 mg ciprofloxacin
Study: 12435668
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro model simulating in vivo pharmacokinetics
Study: 10357120
Drug: Deflazacort oral
Normalized name: deflazacort Oral Tablet
DrugBank: Deflazacort (DB11921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deflazacort oral drops
Study: 10357120
Drug: Deflazacort oral
Normalized name: deflazacort Oral Tablet
DrugBank: Deflazacort (DB11921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deflazacort oral tablets
Study: 6787746
Drug: High voltage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High voltage therapy of the retrobulbar region
Study: 30683945
Drug: IIGI+saline (154
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIGI+saline (154 mmol/l NaCl; placebo)
Study: 24073975
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg and 50 mg
Study: 19169684
Drug: Fotemustine (100-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotemustine (100-75 mg/m2) administered every three weeks followed by fotemustine (100 mg/m2) every three weeks after a 5-week rest for up to 1 year.
Study: 19169684
Drug: Induction phase
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction phase of fotemustine treatment.
Study: 19169684
Drug: Maintenance phase
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance phase of fotemustine treatment.
Study: 16755856
Drug: Vilarinum in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilarinum in addition to conventional treatment (beta‐adrenoblockers, antiaggregants, and statins)
Study: 9823645
Drug: Artroflow device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artroflow device used three times a day for 30 minutes in addition to Enoxaparin 1 x 40 mg subcutaneously per day.
Study: 9823645
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only Enoxaparin 1 x 40 mg subcutaneously per day.
Study: 2560621
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus adjuvant chemotherapy (n = 8)
Study: 785735
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg matrix isoniazid
Study: 785735
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of matrix isoniazid
Study: 785735
Drug: 30-40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-40 mg/kg matrix isoniazid
Study: 27862308
Drug: Alemtuzumab consolidation
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab consolidation therapy (10 mg intravenously once weekly for 8 weeks, escalating in 10 mg intervals)
Study: 25481662
Drug: Palliative concurrent
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative concurrent chemoradiotherapy (CRT) with 4 courses of intravenous carboplatin and oral vinorelbine, plus radiotherapy (42 Gy in 15 fractions)
Study: 23774931
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) of propofol and remifentanil
Study: 23774931
Drug: Manual-controlled infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual-controlled infusion (MCI) of propofol and remifentanil
Study: 21627767
Drug: Micro-TENS therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-TENS therapy
Study: 19366842
Drug: follicle-stimulating hormone
Normalized name: Follicle-stimulating hormone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: follicle-stimulating hormone (FSH)
Study: 11733092
Drug: Pulsatile release
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile release tablets containing 60 mg DIL
Study: 9390586
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with bupivacaine 0.125% and fentanyl 10 microg/mL
Study: 9390586
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) with morphine (0.05 mg/kg bolus, 0.02 mg/kg on demand every 10 min)
Study: 3170796
Drug: Nickel sulfate
Normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulfate in aqueous solutions
Study: 3170796
Drug: Nickel bioavailability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel bioavailability from earrings and necklace
Study: 3170796
Drug: Plasma solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma solution for leaching
Study: 3170796
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution and synthetic sweat
Study: 18276741
Drug: Rituximab 1
Normalized name: rituximab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 1 g (2 infusions)
Study: 8865128
Drug: CDDP 40
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP 40 mg/m2 + VP16 100 mg/m2 day 1‐3 (arm A)
Study: 8865128
Drug: CBDCA 250
Normalized name: CBDCA
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CBDCA 250 mg/m2 day 1 + CDDP 30 mg/m2 day 2, 3 + VP16 100 mg/m2 day 1‐3 (arm B)
Study: 1641586
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine once daily
Study: 29557400
Drug: 5.0 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mm implants
Study: 29557400
Drug: 10.0 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mm or longer implants
Study: 25263780
Drug: Control enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control enriched with 100 g/kg of extruded linseed
Study: 25263780
Drug: Control enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control enriched with 200 g/kg of extruded linseed
Study: 20145166
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 day 1 every 3 weeks)
Study: 18042476
Drug: Multivitamin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplementation (mecobalamin 500 mg + multivitamin supplement containing B6 5 mg, folic acid 1 mg)
Study: 8389269
Drug: Ulinastatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (100 U/mL)
Study: 3548612
Drug: 50% branched
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% branched chain enriched formula (MAA) (Travasol + Branchamin concentrate) at a dose of 1.0-2.0 g/kg/day
Study: 3548612
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid formula (SAA) (Travasol) at a dose of 1.0-2.0 g/kg/day
Study: 1382291
Drug: Erythemagenic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythemagenic doses of UVB prior to sensitization with DNCB
Study: 1382291
Drug: Erythemagenic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythemagenic doses of UVB
Study: 29907082
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (Div group)
Study: 29907082
Drug: 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD0.5 group)
Study: 29907082
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD1.0 group)
Study: 29907082
Drug: 2.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD2.0 group)
Study: 22317271
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality based therapy (VRBT)
Study: 20013927
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g co-amoxiclav (prophylactic dose)
Study: 20013927
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (control)
Study: 10730687
Drug: Argatroban 125-microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban 125-microg/kg bolus followed by 4-hour continuous infusion of 2.5 microg/kg/minute (Study 1)
Study: 10730687
Drug: Argatroban 4-hour
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban 4-hour infusion of 2.5 microg/kg/minute (Study 2)
Study: 10730687
Drug: Argatroban 5-microg/kg/minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban 5-microg/kg/minute continuous infusion over 4 hours (Study 3)
Study: 31201218
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days, titrated to a maximum of 15 g over 4 weeks.
Study: 29717473
Drug: Inhalable doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalable doxorubicin (25 mg/m2)
Study: 29717473
Drug: Cisplatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (10 mg/m2)
Study: 22935482
Drug: Albuminuria at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuminuria at 1-2 μg/min
Study: 12440139
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of INH per day for 6 months
Study: 7028200
Drug: Naloxone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.3 mg/Kg b.wt.)
Study: 23816960
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus pemetrexed chemotherapy
Study: 19430098
Drug: Antiretroviral treatment-experienced
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment-experienced patients
Study: 19430098
Drug: Antiretroviral treatment-naive
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment-naive patients
Study: 19430098
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of polymerase domain between treatment-experienced and treatment-naive patients